![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Arthritis Drug With Narrower Indication
FDA Approves Arthritis Drug With Narrower Indication
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
June 4, 2018
The FDA issued a narrower approval than expected for the Eli Lilly and Incyte rheumatoid arthritis drug Olumiant (baricitinib).
The drug was initially seen as a potential blockbuster with projected peak sales of $2 billion. Last year, however, the FDA rejected it, citing concerns about rates of infection, clotting and cancerous growths.
The agency approved a lower, less effective dosage of the drug, which will carry a black-box warning about potential safety hazards. The drug’s indication will also be restricted to patients whose rheumatoid arthritis has remained after treatment with immunosuppressants.
Upcoming Events
-
21Oct